Latest market price
18.32
-0.30-1.61%
OverviewShort InterestFilings
SRPTQT54Sarepta Therapeutics, Inc.·NASDAQ
18.32-1.61%
TA
Loading chart...
Signal & projected range
Short-squeeze setupHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
TRVI+0.52%$13.63FTRE-5.97%$20.02MESO-4.09%$14.54VIR-2.65%$11.00SEPN-1.82%$43.20XERS-5.04%$10.17REPL+10.68%$19.49PGEN-25.94%$5.14
Snapshot
Index—P/E—EPS (ttm)-2.90Insider Own7.67%Shs Outstand105.63MPerf Week1.89%
Market Cap1.94BForward P/E53.19EPS next Y0.34Insider Trans0.00%Shs Float100.45MPerf Month4.69%
Enterprise Value2.19BPEG—EPS next Q0.07Short Float22.23%Perf Quarter11.78%
Income-137.00MP/S0.98EPS this Y—Short Ratio7.49Perf Half Y-16.88%
Sales1.97BP/B1.27EPS next Y-88.83%ROA-4.29%Short Interest22.33MPerf YTD-14.87%
Book/sh14.47P/C2.46EPS next 5Y—ROE-9.96%52W High24.68 -25.77%Perf Year-21.20%
Cash/sh7.46P/FCF—EPS past 3/5Y—ROIC-5.33%52W Low14.68 24.80%Perf 3Y-83.58%
Dividend Est.—EV/EBITDA—Sales past 3/5Y33.06% 32.41%Gross Margin58.56%Volatility4.95% 4.96%Perf 5Y-77.01%
Dividend TTM—EV/Sales1.11EPS Y/Y TTM—Oper. Margin-7.26%ATR (14)0.96Perf 10Y-61.82%
Dividend Ex-Date—Quick Ratio2.62Sales Y/Y TTM-20.44%Profit Margin-6.93%RSI (14)49.13Recom2.55
Dividend Gr. 3/5Y—Current Ratio4.42EPS Q/Q-102.48%SMA201.70%Beta0.45Target Price21.60
Payout0.00%Debt/Eq0.68Sales Q/Q-34.37%SMA50-4.74%Rel Volume0.41Prev Close18.62
Employees835LT Debt/Eq0.68EarningsNov 05SMA200-2.08%Avg Volume2.86MPrice18.32
IPO DateJun 04, 1997Option/ShortYes / YesEPS/Sales Surpr.-123.01% 9.51%Net Debt/EBITDA—Volume1,158,963Change-1.61%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-08-26ReiteratedRBC CapitalSector Perform$17
Jul-27-26ReiteratedMorgan StanleyEqual Weight$25
Jul-09-26ReiteratedPiper SandlerNeutral$16 → $20
Jul-09-26UpgradeWolfe ResearchPeer Perform → Outperform$27
May-15-26ReiteratedEvercore ISIOutperform$20 → $19
Mar-26-26ReiteratedDeutsche BankSell$12 → $14
Mar-26-26ReiteratedWedbushOutperform$29 → $35
Mar-03-26ReiteratedLoop Capital Markets$25
Mar-03-26ReiteratedJefferiesBuy$30
Jan-27-26ReiteratedRobert W. Baird$15 → $22
Latest News· Times ET
Oct-29-26
Oct-29-2611:02AM
Sarepta Therapeutics (SRPT) Earnings Expected to Grow: Should You Buy?zacks.com
Oct-28-26
Oct-28-2605:24AM
Was The Run In Moderna Stock Hiding In Plain Sight?Yahoo
Oct-26-26
Oct-26-2604:30PM
Sarepta Therapeutics to Present at Upcoming Investor Conferencesbusinesswire.com
Oct-23-26
Oct-23-2604:00AM
How Much Downside Is Left In Moderna Stock?Yahoo
Oct-22-26
Oct-22-2608:30AM
Sarepta Therapeutics to Announce Third Quarter 2026 Financial Resultsbusinesswire.com
Oct-19-26
Oct-19-2608:14AM
Analyzing Protagonist Therapeutics (NASDAQ:PTGX) and Sarepta Therapeutics (NASDAQ:SRPT)defenseworld.net
Oct-16-26
Oct-16-2610:44AM
What Is The Case For Waiting On Moderna Stock?Yahoo
Oct-14-26
Oct-14-2608:30AM
Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meetingbusinesswire.com
Oct-12-26
Oct-12-2605:01PM
Where Could Moderna's Next Growth Come From?Yahoo
Oct-06-26
Oct-06-2604:17AM
Jim Cramer: This Tech Stock Is 'Very Good,' Avery Dennison Is A ‘Winner’Benzinga
Oct-05-26
Oct-05-2601:26PM
Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPTbusinesswire.com
08:07AM
Sarepta Therapeutics (NASDAQ:SRPT) Given Sell Rating at HC Wainwrightdefenseworld.net
Sep-30-26
Sep-30-2604:30PM
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)businesswire.com
09:30AM
Dyne: Recent Price Drop On Rival's DM1 Data Creates (Risky) 'Buy The Dip' ScenarioSeekingAlpha
08:30AM
Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Older Ambulatory Patients with Duchennebusinesswire.com
Company

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company currently offers two approved treatments: EXONDYS 51, prescribed for Duchenne muscular dystrophy (DMD) patients with confirmed dystrophin gene mutations amenable to exon 51 skipping, and VYONDYS 53, for DMD patients with exon 53 skipping mutations. Sarepta's development pipeline includes AMONDYS 45, an exon-skipping product candidate utilizing phosphorodiamidate morpholino oligomer chemistry for exon 45; SRP-5051, a peptide-conjugated PMO designed to target exon 51 of dystrophin pre-mRNA; and gene therapy programs such as SRP-9001 for DMD and SRP-9003 for limb-girdle muscular dystrophies. The company maintains collaborative agreements with organizations like F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, Lysogene, Duke University, Genethon, and StrideBio. Founded in 1980, Sarepta Therapeutics is headquartered in Cambridge, Massachusetts.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue1,9742,1981,9021,243—————
Cost of Goods Sold Incl. D&A818882319150—————
Gross Profit1,1561,3171,5831,093—————
Selling, General and Administrative Excl. Other437479558482—————
Research and Development7891,522805877—————
Other Operating Expense74-2622—————
Operating Income-144-658218-268—————
Interest Expense60101822—————
Unusual Expense
—————————
Non-Operating Income (Expense)70-3561-230—————
Net Income Before Taxes-131-702261-520—————
Income Taxes6112616—————
Consolidated Net Income-137-713235-536—————
Net Income From Continuing Operations-137-713235-536—————
Net Income-137-713235-536—————
EPS (Recurring)-1.44-7.132.47-5.80—————
EPS (Basic, Before Extraordinaries)-1.44-7.132.47-5.80—————
EPS (Diluted)-2.90-7.132.34-5.80—————
EBITDA-15-648317-454—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio——51.96——————
Price To Sales Ratio0.971.036.077.14—————
Gross Margin58.5659.9283.2387.93—————
Operating Margin-7.29-29.9411.46-21.56—————
Net Margin-6.94-32.4412.36-43.12—————
Shares Outstanding1051059592—————
Market Capitalization1,9242,26011,5518,872—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$25.89$22.77$19.66$16.54$13.42● Close Price0.00K73.55K147.10K220.65K294.20KUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Mayo StephenDirectorMar 12 '26Sale17.027,239123,2081,765Mar 13
Estepan Ian MichaelChief Operating OfficerMar 01 '26Option Exercise0.008,1250208,875Mar 03
Rodino-Klapac LouisePresident, R&D and Tech OpsMar 01 '26Option Exercise0.008,1250232,155Mar 03
Estepan Ian MichaelChief Operating OfficerFeb 26 '26Option Exercise13.717,450102,140200,750Mar 02
Nicaise ClaudeDirectorJan 29 '26Option Exercise13.7110,500143,95538,312Jan 29
BEHRENS M KATHLEENDirectorJan 27 '26Option Exercise13.7121,000287,910203,976Jan 29
Estepan Ian MichaelChief Operating OfficerDec 16 '25Sale22.3113,187294,202193,300Dec 18
Barry RichardDirectorMay 16 '25Option Exercise32.6312,350402,9812,966,667May 19
Barry RichardDirectorMay 13 '25Option Exercise19.2320,246389,3592,954,317May 15
Nicaise ClaudeDirectorMar 12 '25Option Exercise25.189,746245,40430,303Mar 13
Nicaise ClaudeDirectorMar 12 '25Sale99.642,491248,20327,812Mar 13
Murray DallanChief Customer OfficerMar 07 '25Option Exercise0.005,500033,659Mar 11
Estepan Ian MichaelChief Financial OfficerMar 07 '25Option Exercise0.005,500058,277Mar 11
Rodino-Klapac LouiseHead of R&D, CSOMar 07 '25Option Exercise0.005,500079,818Mar 11
Rodino-Klapac LouiseHead of R&D, CSOMar 06 '25Option Exercise0.0017,500082,822Mar 10
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.